{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:18:06Z","timestamp":1740115086829,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Nature Scientific Foundation of China","award":["31670937","31270982"],"award-info":[{"award-number":["31670937","31270982"]}]},{"DOI":"10.13039\/501100003807","name":"Science and Technology Department Foundation of Jilin Province","doi-asserted-by":"publisher","award":["3D514BK33426"],"award-info":[{"award-number":["3D514BK33426"]}],"id":[{"id":"10.13039\/501100003807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Department Foundation of Jilin Province","award":["20160101221JC, 20160204026YY"],"award-info":[{"award-number":["20160101221JC, 20160204026YY"]}]},{"name":"Jilin Province Development and Reform Commission Foundation","award":["2017C046-4"],"award-info":[{"award-number":["2017C046-4"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.vaccine.2018.04.053","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T02:51:56Z","timestamp":1542336716000},"page":"8148-8157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice"],"prefix":"10.1016","volume":"36","author":[{"given":"Boqi","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiyun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.04.053_b0005","first-page":"ii69","article-title":"Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"18","author":"Group","year":"2007","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0010","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-0296","article-title":"Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma","volume":"74","author":"Schuessler","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.04.053_b0015","doi-asserted-by":"crossref","first-page":"3597613","DOI":"10.1155\/2017\/3597613","article-title":"Advances in immunotherapy for glioblastoma multiforme","volume":"2017","author":"Huang","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2018.04.053_b0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cncr.30371","article-title":"Immunotherapy approaches in the treatment of malignant brain tumors","volume":"123","author":"Dunn-Pirio","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2018.04.053_b0025","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.vaccine.2018.04.053_b0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14712598.2017.1299705","article-title":"Prospect of rindopepimut in the treatment of glioblastoma","volume":"17","author":"Elsamadicy","year":"2017","journal-title":"Exp Opin Biol Therapy"},{"key":"10.1016\/j.vaccine.2018.04.053_b0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jocn.2010.11.034","article-title":"A phase I\/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma","volume":"18","author":"Chang","year":"2011","journal-title":"J Clin Neurosci: Off J Neurosurg Soc Australasia"},{"key":"10.1016\/j.vaccine.2018.04.053_b0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.smim.2010.02.004","article-title":"Whole tumor antigen vaccines","volume":"22","author":"Chiang","year":"2010","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0045","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/sj.cgt.7700975","article-title":"Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma","volume":"13","author":"Fakhrai","year":"2006","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.vaccine.2018.04.053_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/foc.2000.9.6.10","article-title":"Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes","volume":"9","author":"Sloan","year":"2000","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.vaccine.2018.04.053_b0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0060","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.4049\/jimmunol.1201206","article-title":"A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease","volume":"189","author":"Ding","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/nop047","article-title":"Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study","volume":"12","author":"Carpentier","year":"2010","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.vaccine.2018.04.053_b0070","doi-asserted-by":"crossref","unstructured":"Wu A, Oh S, S, Vedi R, Ericson K, Low W, Chen W, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007;30:789\u201397.","DOI":"10.1097\/CJI.0b013e318155a0f6"},{"key":"10.1016\/j.vaccine.2018.04.053_b0075","doi-asserted-by":"crossref","first-page":"e1081328","DOI":"10.1080\/2162402X.2015.1081328","article-title":"Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer","volume":"5","author":"Lee","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.vaccine.2018.04.053_b0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CJI.0000000000000008","article-title":"A bacterial flagellin in combination with proinflammatory cytokines activates human monocyte-derived dendritic cells to generate cytotoxic T lymphocytes having increased homing signals to cancer","volume":"37","author":"Hong","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2018.04.053_b0085","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3892\/etm.2015.2914","article-title":"Expression levels of cytokines and chemokines increase in human peripheral blood mononuclear cells stimulated by activation of the Toll-like receptor 5 pathway","volume":"11","author":"Ma","year":"2016","journal-title":"Exp Therapeut Med"},{"key":"10.1016\/j.vaccine.2018.04.053_b0090","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.3892\/mmr.2015.4276","article-title":"Flagellin influences the expression of a variety of important cytokines and chemokines without affecting the immune status of umbilical cord mesenchymal stem cells","volume":"12","author":"Li","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.vaccine.2018.04.053_b0095","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.4049\/jimmunol.0804225","article-title":"Direct stimulation of tlr5+\/+ CD11c+ cells is necessary for the adjuvant activity of flagellin","volume":"182","author":"Bates","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4049\/jimmunol.182.1.55","article-title":"Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation","volume":"182","author":"McCarron","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.04.053_b0110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clinbiochem.2015.07.099","article-title":"Lymphocyte surface molecules as immune activation biomarkers","volume":"49","author":"Wieland","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.vaccine.2018.04.053_b0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory Pathways in Immunotherapy for Cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0120","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/imt.13.91","article-title":"CD4 T-cell immunotherapy for chronic viral infections and cancer","volume":"5","author":"Kamphorst","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2018.04.053_b0125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4049\/jimmunol.181.1.354","article-title":"Dendritic cells require the NF- B2 pathway for cross-presentation of soluble antigens","volume":"181","author":"Lind","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/intimm\/13.5.675","article-title":"Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines","volume":"13","author":"Yoshimura","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0135","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4049\/jimmunol.178.3.1301","article-title":"An alternative pathway of NF- B activation results in maturation and T cell priming activity of dendritic cells overexpressing a mutated I B","volume":"178","author":"Moore","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4049\/jimmunol.178.1.253","article-title":"Multiple NF- B and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells","volume":"178","author":"Pietila","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0145","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.4049\/jimmunol.169.7.3914","article-title":"Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo","volume":"169","author":"McSorley","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0150","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.4049\/jimmunol.1001855","article-title":"Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88","volume":"186","author":"Bates","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0155","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.vaccine.2013.06.054","article-title":"Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model","volume":"31","author":"Nguyen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.053_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002868","article-title":"Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses","volume":"4","author":"Garaude","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.04.053_b0165","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2003-08-2820","article-title":"Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production","volume":"104","author":"Chalifour","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.04.053_b0170","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1189\/jlb.0105051","article-title":"Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions","volume":"78","author":"Tsujimoto","year":"2005","journal-title":"J Leukocyte Biol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0175","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.4049\/jimmunol.0802845","article-title":"NK cells recognize and kill human glioblastoma cells with stem cell-like properties","volume":"182","author":"Castriconi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0180","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/1078-0432.CCR-09-3087","article-title":"Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy","volume":"16","author":"Alizadeh","year":"2010","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.vaccine.2018.04.053_b0185","first-page":"345","article-title":"Myeloid-derived suppressor cells in gliomas","volume":"20","author":"Gieryng","year":"2016","journal-title":"Contemp Oncol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0190","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/0008-5472.CAN-14-2467","article-title":"TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity","volume":"75","author":"Geng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.04.053_b0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-065X.2008.00607.x","article-title":"The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance","volume":"222","author":"Allavena","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2018.04.053_b0200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2015.00153","article-title":"Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites","volume":"5","author":"Perng","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.nec.2009.08.005","article-title":"Glioblastoma-derived mechanisms of systemic immunosuppression","volume":"21","author":"Waziri","year":"2010","journal-title":"Neurosurg Clin North Am"},{"key":"10.1016\/j.vaccine.2018.04.053_b0210","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2018.04.053_b0215","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1111\/cas.12015","article-title":"Importance of direct macrophage-tumor cell interaction on progression of human glioma","volume":"103","author":"Komohara","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.vaccine.2018.04.053_b0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9537","article-title":"Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin","volume":"9","author":"Zheng","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.04.053_b0225","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4049\/jimmunol.179.2.845","article-title":"Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells","volume":"179","author":"Masson","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.immuni.2004.12.008","article-title":"Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs","volume":"22","author":"Calzascia","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.04.053_b0235","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s11481-013-9470-8","article-title":"Drainage of cells and soluble antigen from the CNS to regional lymph nodes","volume":"8","author":"Laman","year":"2013","journal-title":"J Neuroimm Pharmacol: Off J Soc NeuroImmune Pharmacol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0240","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1227\/01.NEU.0000159649.71890.30","article-title":"Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: initial experience in 51 patients","volume":"56","author":"Patel","year":"2005","journal-title":"Neurosurgery."},{"key":"10.1016\/j.vaccine.2018.04.053_b0245","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2006.08.1117","article-title":"Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group","volume":"25","author":"Kunwar","year":"2007","journal-title":"J Clin Oncol: Offic J Am Soc Clin Oncol"},{"key":"10.1016\/j.vaccine.2018.04.053_b0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02700027","article-title":"Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma","volume":"64","author":"Weber","year":"2003","journal-title":"J Neuro-Oncol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T15:33:16Z","timestamp":1572708796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":50,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0264410X18305504"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}